NASDAQ · CDXS
Healthcare · Biotechnology
$1.05
Up+$0.02 (+1.91%)
Updated Nov 3, 2026, 2:43 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CDXS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
CDXS closed at $1.05 after 21 trading sessions, down 24.82% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $1.20 | $1.22 | $1.04 | $1.045 | 1.13M |
| Oct 30, 2026 | $1.20 | $1.24 | $1.17 | $1.19 | 789.47K |
| Oct 29, 2026 | $1.27 | $1.296 | $1.20 | $1.22 | 917.3K |
| Oct 28, 2026 | $1.28 | $1.33 | $1.25 | $1.26 | 1.65M |
| Oct 27, 2026 | $1.30 | $1.315 | $1.26 | $1.28 | 691.46K |
| Oct 26, 2026 | $1.30 | $1.30 | $1.28 | $1.30 | 392.38K |
| Oct 23, 2026 | $1.30 | $1.32 | $1.265 | $1.28 | 546.63K |
| Oct 22, 2026 | $1.29 | $1.325 | $1.29 | $1.31 | 501.52K |
| Oct 21, 2026 | $1.24 | $1.31 | $1.234 | $1.29 | 1.06M |
| Oct 20, 2026 | $1.32 | $1.35 | $1.21 | $1.23 | 1.29M |
| Oct 19, 2026 | $1.25 | $1.36 | $1.225 | $1.32 | 1.16M |
| Oct 16, 2026 | $1.36 | $1.36 | $1.22 | $1.24 | 980.07K |
| Oct 15, 2026 | $1.29 | $1.36 | $1.264 | $1.36 | 681.1K |
| Oct 14, 2026 | $1.30 | $1.34 | $1.27 | $1.29 | 931.89K |
| Oct 13, 2026 | $1.39 | $1.405 | $1.305 | $1.32 | 820.52K |
| Oct 12, 2026 | $1.40 | $1.43 | $1.315 | $1.41 | 1.1M |
| Oct 9, 2026 | $1.36 | $1.41 | $1.34 | $1.41 | 555.43K |
| Oct 8, 2026 | $1.39 | $1.40 | $1.35 | $1.36 | 887.35K |
| Oct 7, 2026 | $1.33 | $1.445 | $1.33 | $1.41 | 958.2K |
| Oct 6, 2026 | $1.40 | $1.445 | $1.36 | $1.36 | 597.87K |
| Oct 5, 2026 | $1.38 | $1.405 | $1.335 | $1.39 | 894.33K |
The latest Smart Investors Daily articles mentioning CDXS.
Company
Market Activity
Research & News
CDXS research
Company profile and research snapshot.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Piper Sandler | Overweight | — |
| Nov 22, 2024 | Cantor Fitzgerald | Overweight | — |
| Nov 15, 2024 | Cantor Fitzgerald | Overweight | — |
| Nov 4, 2024 | Benchmark | Hold | — |
| Sep 20, 2024 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
White Brook Capital’s Q3 2026 investor letter expresses cautious optimism. Its Ethical All-Cap Strategy has outperformed, while the Small Cap Strategy has lagged because of execution delays, higher interest rates, and market pressure. You can download a copy of the letter here. The economy remains resilient, supported by AI infrastructure investment, consumer spending, healthcare research, […]
Yahoo · Sep 28, 2026
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform. The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise cont
Benzinga · Sep 28, 2026
The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a
Yahoo · Sep 25, 2026
A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CDXS.
